# US 2021/0340516 A1 · Compositions containing arginase 1 for the treatment of neurovascular and retinal vascular disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340516 A1
- Document ID: US20210340516A1
- Status: Published application
- Kind: A1
- Application number: 17/244,385
- Filed: 2021-04-29
- Published: 2021-11-04
- Earliest claimed: 2020-04-29
- Assignees: Augusta University Research Institute, Inc.
- Applicants: Augusta University Research Institute, Inc.; The US Government as Represented by the Department of Veterans Affairs
- Inventors: Ruth CALDWELL
- Web page: https://patentgrep.com/patent/US20210340516A1

## CPC

- C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 27/02: Ophthalmic agents
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12Y 305/03001: Arginase (3.5.3.1)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Pathological retinal neovascularization is a common micro-vascular complication in several retinal diseases including retinopathy of prematurity (ROP), diabetic retinopathy, age-related macular degeneration and central vein occlusion. Disclosed herein are compositions and methods useful for the treatment or prevention of retinal neovascularization and related diseases in a subject in need thereof. Exemplary methods include administering a composition including PEGylated arginase 1 to a subject in need thereof to promote reparative angiogenesis and decrease retinal neovascularization in the eye.

## Claims

### Claim 1

A method of inducing or promoting the regression of retinal neovascularization induced injury in a subject in need thereof, comprising administering to the eye of the subject a composition comprising recombinant arginase 1 in an amount effective to promote reparative angiogenesis and decrease retinal neovascularization in the eye to induce or promote the regression of retinal neovasculariation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the recombinant arginase 1 is PEGylated.

### Claim 3 (depends on 1)

The method of claim 1, wherein the recombinant arginase 1 is administered to the eye of the subject by intravitreal injection.

### Claim 4 (depends on 1)

The method of claim 1, wherein the recombinant arginase 1 is administered to the eye of the subject by topical application.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject in need thereof has retinopathy of prematurity (ROP), diabetic retinopathy, age-related macular degeneration, or retinal vein occlusion.

### Claim 6 (depends on 1)

The method of claim 1, wherein reparative angiogenesis is promoted by an increase in the levels of growth factors in the retina.

### Claim 7 (depends on 6)

The method of claim 6, wherein the growth factors are FGF2 and CNTF.

### Claim 8 (depends on 1)

The method of claim 1, wherein the regression of retinal neovascularization is induced by decreased the production and expression of inflammatory molecules in the retina.

### Claim 9 (depends on 8)

The method of claim 8, wherein the inflammatory molecules are TNFα, IL-6, and MCP1.

### Claim 10

A method of reducing or inhibiting the progression of retinal neovascularization related disease in a subject in need thereof, comprising administering to the subject a composition comprising recombinant arginase 1 in an amount effective to promote reparative angiogenesis and decrease retinal neovascularization in the eye.

### Claim 11 (depends on 10)

The method of claim 10, wherein the recombinant arginase 1 is PEGylated.

### Claim 12 (depends on 10)

The method of claim 10, wherein the recombinant arginase 1 is administered to the eye of the subject by intravitreal injection.

### Claim 13 (depends on 10)

The method of claim 10, wherein the recombinant arginase 1 is administered to the eye of the subject by topical application.

### Claim 14 (depends on 10)

The method of claim 10, wherein the retinal neovascularization related disease is retinopathy of prematurity (ROP), diabetic retinopathy, age-related macular degeneration, or retinal vein occlusion.

### Claim 15

A method of treating retinopathy of prematurity in an infant in need thereof, comprising administering to the infant a composition comprising recombinant arginase 1 in an amount effective to promote reparative angiogenesis and decrease retinal neovascularization in the eye to induce or promote the regression of retinal neovasculariation.

### Claim 16 (depends on 15)

The method of claim 15, wherein the recombinant arginase 1 is PEGylated.

### Claim 17 (depends on 15)

The method of claim 15, wherein the recombinant arginase 1 is administered to the eye of the infant by intravitreal injection.

### Claim 18 (depends on 15)

The method of claim 15, wherein the recombinant arginase 1 is administered to the eye of the infant by topical application.

### Claim 19 (depends on 15)

The method of claim 15, wherein composition is administered to the infant once a week.

### Claim 20 (depends on 15)

The method of claim 15, wherein the composition is administered to the infant once a month.

### Claim 21 (depends on 15)

The method of claim 15, wherein administration of recombinant arginase prevents blindness in the infant.

### Claim 22

An ophthalmic composition comprising pegylated arginase 1.

### Claim 23

A method of preventing or treating neurodegeneration in a subject in need thereof, comprising administering to the subject a composition comprising recombinant arginase 1 in an amount effective to promote neuroprotection or neurogenesis.

### Claim 24 (depends on 23)

The method of claim 23, wherein the recombinant arginase 1 is PEGylated.

### Claim 25 (depends on 23)

The method of claim 23, wherein neurodegeneration in a subject is the result of an ischemic injury to the brain or eye.

### Claim 26 (depends on 25)

The method of claim 25, wherein the ischemic injury is an ischemic stroke or ischemic retinopathies.

### Claim 27 (depends on 25)

The method of claim 25, wherein systemic administration of recombinant arginase 1 provides promotes neuroprotection from ischemic injury to the retina or brain by penetrating the blood-retina or blood brain barrier of a subject with prior ischemic injury to the retina or brain.

### Claim 28 (depends on 23)

The method of claim 23, wherein neurodegeneration in a subject is the result of acute retinal injury, wherein the acute retinal injury results in traumatic optic neuropathy.

### Claim 29 (depends on 28)

The method of claim 28, wherein systemic administration of recombinant arginase 1 provides promotes neuroprotection from traumatic optic neuropathy by penetrating the blood-retina barrier of a subject with acute retinal injury.
